個(gè)人簡介：
肖榮權(quán)，南方科技大學(xué)醫(yī)學(xué)院研究助理教授。2020年獲得廈門大學(xué)理學(xué)博士學(xué)位，導(dǎo)師為劉文教授。主要從事癌癥等重大疾病的表觀遺傳分子機(jī)制及其應(yīng)用研究。研究工作發(fā)表于Molecular Cell，Proc Natl Acad Sci U S A和ACS Medicinal Chemistry Letters等國際學(xué)術(shù)期刊。主持國家自然科學(xué)基金青年科學(xué)基金項(xiàng)目、中國博士后科學(xué)基金面上資助（二等）和深圳市醫(yī)學(xué)研究專項(xiàng)資金項(xiàng)目（人才提升型-青年項(xiàng)目）各1項(xiàng)。申請(qǐng)專利4項(xiàng)，其中3項(xiàng)已經(jīng)獲得授權(quán)。
教育背景：
2014/09 - 2020/06 廈門大學(xué), 化學(xué)生物學(xué), 博士
2009/09 - 2013/07 上海師范大學(xué), 生物技術(shù), 學(xué)士
工作經(jīng)歷：
2023/06 - 至今 南方科技大學(xué), 醫(yī)學(xué)院, 研究助理教授
2020/07 - 2023/06 廈門大學(xué), 藥學(xué)院，博士后
獲獎(jiǎng)情況及榮譽(yù)：
廈門大學(xué)生命科學(xué)與人類健康學(xué)科群2021年度優(yōu)秀博士后資助，2021
廈門大學(xué)“優(yōu)秀畢業(yè)生”榮譽(yù)稱號(hào)，2020
廈門大學(xué)藥學(xué)院“莊瑾獎(jiǎng)學(xué)金”突出貢獻(xiàn)獎(jiǎng)，2018
研究領(lǐng)域：
表觀遺傳調(diào)控因子在腫瘤中的功能、分子機(jī)制及其應(yīng)用研究
發(fā)表論文：
1. Xiao RQ, Ran T, Huang QX, Hu GS, Fan DM, Yi J, Liu W. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34): e2200753119.
2. Gao WW#, Xiao RQ#, Zhang WG#, Hu YR#, Peng BL, Li WJ, He YH, Shen HF, Ding JC, Huang QX, Ye TY, Li Y, Liu ZY, Ding R, Rosenfeld MG, Liu W. JMJD6 licenses estrogen receptor a-dependent enhancer and coding gene activation by modulating the recruitment of the CARM1/MED12 co-activator complex. Molecular Cell. 2018 April 19;70(2): 340-357. (# 共同第一作者)
3. Ran T#, Xiao RQ#, Huang QX, Yuan HL, Lu T, Liu W. In Silico Discovery of JMJD6 Inhibitors for Cancer Treatment. ACS Medicinal Chemistry Letters. 2019 Nov 19, 10: 1609-1613. (# 共同第一作者)
4. Gao WW, Xiao RQ, Peng BL, Xu HT, Shen HF, Huang MF, Shi TT, Yi J, Zhang WJ, Wu XN, Gao X, Lin XZ, Dorrestein PC, Rosenfeld MG, Liu W. Arginine methylation of HSP70 regulates retinoid acid-mediated RARβ2 gene activation. Proc Natl Acad Sci U S A. 2015 Jun 30;112(26): E3327-36.
5. Yi J, Wang L, Du J, Wang MY, Shen HF, Liu ZY, Qin Y, Liu J, Hu GS, Xiao RQ, Ding JC, Chen HJ, Wang HJ, Huang HH, Ouyang GL, Liu W. ER-localized JmjC domain-containing protein JMJD8 targets STING to promote immune evasion and tumor growth in breast cancer. Developmental Cell. 2023 May 8, 58(9): 760-778.
6. Peng BL, Li WJ, Ding JC, He YH, Ran T, Xie BL, Wang ZR, Shen HF, Xiao RQ, Gao WW, Ye TY, Gao X, Liu W. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor a-dependent transcriptional activation and breast carcinogenesis. Theranostics. 2020 Feb 10; 10(8): 3451-3473.
7. Zhang WJ, Wu XN, Shi TT, Xu HT, Yi J, Shen HF, Huang MF, Su XY, Wang FF, Peng BL, Xiao RQ, Gao WW, Ding JC, Liu W. Regulation of Transcription Factor Yin Yang 1 by SET7/9-mediated Lysine Methylation. Scientific Reports. 2016 Feb 23; 6: 21718.
8. Ye F, You J, Xia L, Lian JB, Xiao RQ, Ran T, Gao X, Li JY, Zhao X, Gao J, Lin HX, Zheng JN, Liu W. Patient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer. Annals of Oncology. 2019 Oct; 30: v238-v239.
